Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.

Blood · 2023 · PMC10651879 · PMID 37018663

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Serial transplantation of the residual CML cells showed a trend of decrease in the CML engraftment in secondary recipients receiving BM cells from primary recipients who had been treated with CXCL14 ( supplemental Figure 8 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.